FIELD: molecular biology, genetic therapy, pharmacy. SUBSTANCE: invention relates to retroviral vector subjecting for promoter conversion comprising region 5'-long terminal repeat region from structure U3-R-U5; one or more sequences taken among encoding and non-encoding sequences; and region 3'-long terminal repeat region comprising the complete or partially deleted region U3. Indicated deleted region U3 is replaced for polylinker sequence after that regions R and U5 follow. Retroviral vector is subjected for promoter conversion and can be used as a carrier for gene transfer to carry out the directed genetic therapy. EFFECT: valuable properties of construction. 27 cl, 10 dwg, 3 ex
Title | Year | Author | Number |
---|---|---|---|
RETROVIRAL VECTORS TRANSDUCING CYTOCHROME P450 | 1997 |
|
RU2185821C2 |
RECOMBINANT MODIFIED SMALLPOX VIRUS, ITS USAGE (VERSIONS) AND CELL LINE INFECTED BY VIRUS (VERSIONS) | 1996 |
|
RU2198217C2 |
CAPSULE FOR CELLS PRODUCING VIRAL PARTICLES, METHOD OF ITS PREPARING AND USING | 1996 |
|
RU2187301C2 |
RECOMBINANT MODIFIED VIRUS OF VACCINE ANKARA ABLE TO EXPRESS HEPATITIS C VIRUS STRUCTURAL ANTIGENS | 2002 |
|
RU2270860C2 |
OZONE-INDUCED GENE EXPRESSION IN PLANTS | 1997 |
|
RU2224021C2 |
CYTOCHROME P-450-TRANSDUCING RETROVIRAL VECTORS | 1997 |
|
RU2223788C2 |
AGENTS AND METHODS OF TREATING HEPATITIS B VIRUS | 2017 |
|
RU2740802C2 |
APPLICATION OF ADAPTED RECOMBINASES FOR CURING OF RETROVIRAL INFECTIONS | 2008 |
|
RU2501860C2 |
IMPROVING GENETIC CONSTRUCTS FOR PROVIDING HIGH EFFICACY OF ANTI-HIV THERAPY | 2013 |
|
RU2533817C1 |
RETROVIRAL VECTOR BASED ON MURINE LEUKOSIS VIRUS (MLV) (VERSIONS) | 1999 |
|
RU2203321C2 |
Authors
Dates
2003-02-27—Published
1995-09-01—Filed